stoxline Quote Chart Rank Option Currency Glossary
Synaptogenix, Inc. (SNPX)
0.2648  0.006 (2.24%)    12-01 15:59
Open: 0.26
High: 0.2649
Volume: 114,602
Pre. Close: 0.259
Low: 0.2499
Market Cap: 3(M)
Technical analysis
2023-12-01 4:22:46 PM
Short term     
Mid term     
Targets 6-month :  0.32 1-year :  0.37
Resists First :  0.28 Second :  0.31
Pivot price 0.25
Supports First :  0.21 Second :  0.18
MAs MA(5) :  0.25 MA(20) :  0.26
MA(100) :  0.45 MA(250) :  0.91
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  48.5 D(3) :  45.3
RSI RSI(14): 42.5
52-week High :  6.24 Low :  0.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SNPX ] has closed above bottom band by 47.6%. Bollinger Bands are 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.27 - 0.27 0.27 - 0.27
Low: 0.25 - 0.25 0.25 - 0.25
Close: 0.25 - 0.25 0.25 - 0.26
Company Description

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Headline News

Thu, 02 Nov 2023
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd ... - PR Newswire

Tue, 26 Sep 2023
Synaptogenix Announces Peer-Reviewed Publication of NIH ... - PR Newswire

Fri, 22 Sep 2023
U.S. stocks lower at close of trade; Dow Jones Industrial Average ... -

Thu, 07 Sep 2023
Best Penny Stocks To Buy Now? 3 Under $1 To Watch - Penny Stocks

Thu, 07 Sep 2023
Bryostatin-1 from Synaptogenix Shows Statistically Significant ... - PR Newswire

Wed, 19 Jul 2023
Synaptogenix and Cleveland Clinic to Submit Investigational New ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 10 (M)
Shares Float 20 (M)
Held by Insiders 9.6 (%)
Held by Institutions 3.6 (%)
Shares Short 953 (K)
Shares Short P.Month 1,400 (K)
Stock Financials
EPS -0.86
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.52
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -25.3 %
Return on Equity (ttm) -2.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.19
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.3
PEG Ratio 0
Price to Book value 0.16
Price to Sales 0
Price to Cash Flow -0.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android